Tag:
Belatacept
Latest Headlines
Latest Headlines
Bristol-Myers on a roll as it snags an approval for belatacept
A little more than a year after the FDA decided to take a wait-and-see approach on Bristol-Myers Squibb's Nulojix (belatacept), federal regulators have finally blessed the marketing application for
Regulators delay a final decision on BMS' belatacept
Bristol-Myers Squibb is going to have to wait a while longer before it knows whether the FDA will allow it to market belatacept to help prevent patients' immune systems from rejecting new kidney
FDA panel backs BMS' new transplant therapy
An FDA advisory panel has voted to back Bristol-Myers Squibb's belatacept, a new therapy designed to prevent the rejection of new kidney transplants. The experts voted 13 to 5 in favor of
